| __timestamp | Axsome Therapeutics, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 35942000 |
| Thursday, January 1, 2015 | 2419289 | 40028000 |
| Friday, January 1, 2016 | 6343648 | 45853000 |
| Sunday, January 1, 2017 | 7206691 | 53816000 |
| Monday, January 1, 2018 | 9351522 | 60804000 |
| Tuesday, January 1, 2019 | 13598030 | 77252000 |
| Wednesday, January 1, 2020 | 28896749 | 45736000 |
| Friday, January 1, 2021 | 66646205 | 50323000 |
| Saturday, January 1, 2022 | 159253661 | 143526000 |
| Sunday, January 1, 2023 | 323123000 | 149182000 |
| Monday, January 1, 2024 | 411359000 | 154335000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational expenses is crucial for sustainable growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Axsome Therapeutics, Inc. over the past decade.
From 2014 to 2023, Axsome Therapeutics saw a staggering increase in SG&A expenses, growing from approximately $1.4 million to over $323 million, marking a growth of over 23,000%. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Halozyme Therapeutics maintained a more stable trajectory, with expenses rising from around $36 million to $149 million, a growth of about 314%.
This divergence highlights different strategic approaches: Axsome's rapid scaling versus Halozyme's steady growth. Investors and stakeholders can glean insights into each company's operational efficiency and strategic priorities, offering a window into their future potential.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.